IGM Biosciences (IGMS, +15%) is seeing another sharp gain, leaving technical levels well behind.
Piper Sandler listed the company today as a potential oncology takeover target after Gilead Sciences’ buyout of Immunomedics.
IGMS is among a list of companies with assets Piper says “are both largely de-risked and target high value indications.”
https://seekingalpha.com/news/3615413-igm-biosciencesplus-15-named-possible-takeover-target
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.